IHH Healthcare Berhad has announced the commencement of the tendering period for open offers involving Fortis Healthcare Limited and Fortis Malar Hospitals Limited. The open offers, set to run from October 20, 2025, to November 4, 2025, mark a significant development in the healthcare sector.

Key Details of the Open Offers

• Fortis Healthcare Open Offer: Aims to acquire up to 197,025,660 shares, representing 26.10% of the expanded voting share capital.
• Fortis Malar Open Offer: Targets up to 4,894,308 shares, representing 26.11% of the voting share capital.
• Subscription Details: The transaction involves Northern TK Venture Pte Ltd, an indirect wholly-owned subsidiary of IHH, subscribing to 235,294,117 new Fortis shares through preferential allotment.

Timeline and Recommendations

• Tendering Period: October 20, 2025, to November 4, 2025
• IDC Recommendations: Published on October 16, 2025
• Pre-offer Advertisements: Scheduled for October 17, 2025

The Committees of Independent Directors (IDC) of both Fortis Healthcare and Fortis Malar Hospitals have published their recommendations regarding the respective open offers. These recommendations will be included in the pre-offer advertisements.

Additional Corporate Actions

In a separate development, Fortis Healthcare Limited has initiated a postal ballot process for shareholder approval on the appointment of Dr. Keith Hsiu Chin Lim as a Non-Independent & Non-Executive Director of the company. Dr. Lim, who currently serves as the Group Chief Medical Officer at IHH Healthcare, brings over 20 years of experience as a radiation oncologist to the board.

The postal ballot notice, dated October 1, 2025, outlines the voting process, which will be conducted through both physical ballot forms and e-voting. Shareholders are required to cast their votes by November 15, 2025.

This series of corporate actions underscores the ongoing changes in Fortis Healthcare's governance structure and ownership, potentially impacting its strategic direction in the coming years.

Fortis Healthcare Limited , a prominent player in the Indian healthcare sector, has initiated a postal ballot process to seek shareholder approval for the appointment of Dr. Keith Hsiu Chin Lim as a Non-Independent & Non-Executive Director on its Board. This move comes as part of the company's ongoing efforts to strengthen its leadership team and enhance corporate governance.

Key Details of the Appointment

• Nominee Director: Dr. Lim's nomination comes from Northern TK Venture Pte. Limited, signaling a strategic alignment with one of Fortis Healthcare's key stakeholders.
• Appointment Date: Dr. Lim was initially appointed as an Additional Director on September 09, 2025.
• Shareholder Approval: The company is now seeking ratification of this appointment through a postal ballot, in compliance with regulatory requirements.
• Voting Period: Shareholders can cast their votes from October 17, 2025, to November 15, 2025.
• Results Declaration: The outcome of the postal ballot is scheduled to be announced by November 18, 2025.

Professional Background of Dr. Keith Hsiu Chin Lim

Dr. Lim brings a wealth of experience to the Fortis Healthcare board:

• Current Role: Group Chief Medical Officer at IHH Healthcare
• Medical Qualifications:
  • MBBS from National University of Singapore
  • Fellow of the Royal Australian and New Zealand College of Radiologists
• Experience: Over 20 years as a radiation oncologist
• Academic Contributions: Previously served as Assistant Dean at the NUS School of Medicine
• Research Impact: His research has been cited over 2,000 times
• Funding Success: Secured over S$2.50 million in research funding

Previous Roles and Achievements

• Group Chief Value Officer at National University Health System (NUHS), Singapore
• Director of Clinical Outcomes and Value at Singapore's Ministry of Health
• Recipient of Singapore's National Medical Excellence Award

Implications for Fortis Healthcare

The appointment of Dr. Lim, with his extensive experience in healthcare management and policy, could potentially bring valuable insights to Fortis Healthcare's operations and strategic direction. His background in value-based healthcare and clinical quality improvement aligns well with the evolving healthcare landscape in India, where there is an increasing focus on quality care and cost-effectiveness.

Shareholders are encouraged to review the detailed postal ballot notice and exercise their voting rights on this important corporate action. The outcome of this vote will be crucial in shaping the future leadership of Fortis Healthcare Limited.

As the healthcare sector continues to evolve, especially in the wake of global challenges, the expertise of leaders like Dr. Lim may prove instrumental in navigating the complex landscape of healthcare delivery and management.